Used in pharmaceutical research as a potent and selective inhibitor of Janus kinase 1 (JAK1), showing promise in the treatment of autoimmune and inflammatory diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Its structure enables high selectivity for JAK1 over other JAK family members, potentially reducing side effects commonly associated with broader JAK inhibition. Currently investigated in preclinical and clinical studies for its efficacy, pharmacokinetic profile, and safety in modulating immune responses. Also serves as a lead compound for developing new oral therapies targeting cytokine signaling pathways involved in chronic inflammation.